IRVINE, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the results of a 10 year study in which Deep Brain Stimulation (DBS) leads were implanted in a diagnostic MRI suite. The study was published in the March, 2016 issue of the Journal of Neurosurgery and outlines a 10 year history of 164 interventional MRI Deep Brain Stimulation procedures, in which 272 leads were implanted. All electrode placement procedures were performed at the University of California San Francisco (UCSF) Medical Center in a diagnostic 1.5T MRI scanner, and patients returned 1–3 weeks later to undergo placement of the implantable pulse generator (IPG) in a conventional operating room. After mid 2010 the electrode implant procedure was performed entirely in the diagnostic MRI suite using the ClearPoint NeuroNavigation System and accessories. There were zero infections related to electrode placement in all 115 electrode implant procedures using the ClearPoint System.
“The study’s finding of zero infections related to the electrode placement stage utilizing the ClearPoint NeuroNavigation is excellent,” stated Frank Grillo, Chief Executive Officer for MRI Interventions. “Also noteworthy is that the only infections reported in the study were either related to the implantation of the IPG or were associated with electrode placement or procedure preparation outside of the MRI suite, prior to ClearPoint’s commercial availability. We believe this paper is a great illustration of the safety of performing ClearPoint procedures in a diagnostic MRI suite.”
The ClearPoint system allows surgeons to plan, target, and adjust trajectories under real time MRI-guided visualization for placement of electrodes, catheters and biopsy needles. The entire procedure takes place in the MRI suite, and eliminates the need to move the patient to and from an operating room and an MRI suite.
“We were very pleased, although not surprised, to see these results indicating the absence of infections related to electrode placement in the MRI suite,” said Dr. Paul Larson, Professor and Vice Chair of Clinical Neurological Surgery at UCSF, and a co-author of the paper. “In addition, the overall clinical outcomes were comparable to those for conventional awake implantation approaches for electrode placement. Our experience with this procedure enables us to make the therapy available to a wider range of patients, including pediatric patients.”
An abstract of the paper can be read here: http://thejns.org/doi/abs/10.3171/2015.7.JNS15750
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of the Company’s products; its ability to successfully expand and achieve full productivity from its sales, clinical support and marketing capabilities; its ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of its cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact its commercialization efforts. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission.